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Abstract
Several different peptides and proteins, such as the pancreatic trypsin inhibitor, growth factors and trefoil peptides, are known to play
important roles in maintaining the structure and function of the gastrointestinal wall. With the advent of recombinant biotechnology, it has
become feasible to test some of these proteins as therapeutics in different in¯ammatory conditions of the intestines. However, the harsh pH
and enzymatic conditions of the stomach can lead to their inactivation. This research was aimed at the development of particulate, gastric-
resistant pharmaceutical forms, incorporating those bioactive molecules. Mixtures of proteins in powder form were coated with cellulose
acetate phthalate, Eudragitw S100 or Eudragitw RS PO, using simple preparation techniques based on single emulsion/solvent evaporation.
Using aprotinin as a model drug, it was found that these procedures were effective in microencapsulating protein in the solid form without
affecting its biological activity. Furthermore, and in particular with the ®rst two polymers above, particles showed adequate in vitro release
patterns for the applications envisioned. q 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Different in¯ammatory conditions of the gastrointestinal
(GI) tract are among the most common clinical situations.
Diseases of this type include gastric and duodenal ulcers,
ulcerative colitis, or Crohn's disease [1]. In all of these
conditions, the mechanisms of mucosal homeostasis have
become impaired.
The normal structure and functioning of the GI epithelia
are guaranteed, among others, by the action of over 20
different peptides and small molecular weight (MW)
proteins, such as transforming growth factors, trefoil
peptides, epidermal growth factor, and pancreatic secretory
trypsin inhibitor [1]. Advances in biotechnology have lead
to the availability of some synthetic and recombinant forms
of these proteins and peptides. One may consider, then, the
administration of these molecules in therapies of the above
pathologies [2,3]. Due to their luminal action, oral admin-
istration can be adequate and convenient. However, the
stress conditions of the GI, such as the low pH in the
stomach and the proteolytic activities in both the stomach
and the small intestine, may lead to their early and irrever-
sible inactivation [4±6]. So, adequate pharmaceutical forms,
that protect those proteins and release them at the damaged
sites, are to be developed and tested.
Particulate pharmaceutical forms have shown several
advantages over other forms, such as more uniform transit
times through the GI tract, less variability among indivi-
duals, and a smaller risk of dose dumping and high local
concentrations.
In this study, trypsin inhibitor from bovine lung, aprotinin
(Apro), was selected as the model drug. This molecule is
similar to the trypsin inhibitor produced in the pancreas,
which protects the organ from damage by prematurely acti-
vated proteases, or produced in various other tissues, such as
the foveolar cells of the GI lining, that protect the mucus
layer from excessive digestion [1].
As the concentrations of the Apro needed at the mucosal
surface are quite small, the formulations developed also
include a bulking agent, in this case, casein from bovine
milk. This selection was based on previous studies which
showed that casein can protect other proteins from the
action of pancreatic enzymes [5,6].
Among the coating materials that looked adequate for this
application, the polymers cellulose acetate phthalate (CAP),
* Corresponding author. Escola Superior de Biotecnologia, U.C.P., Rua
Dr AntoÂnio Bernardino de Almeida, 4200-072 Porto, Portugal. Tel.: 1351-
22-5580027; fax: 1351-22-5090351.
E-mail address: jpf@esb.ucp.pt (J.P.M. Ferreira).
and the polyacrylates Eudragitw S100 (E S100) and Eudra-
gitw RS PO (E RSPO) were selected. The ®rst two materials
are gastro-resistant, and become soluble at neutral and alka-
line pHs; the third one is insoluble in water and digestive
juices, but it is permeable and swells in solution. Among the
various alternative methods to produce small coated parti-
cles, techniques of emulsion/solvent evaporation were
employed.
2. Materials and methods
2.1. Materials
These included: CAP (Schultz & Co., Germany);
Eudragitw RS PO (E RSPO), Eudragitw S100 (E S100;
Rohm Pharma, Germany); technical grade casein from
bovine milk, trypsin, benzoyl-dl-arginine-p-nitroanilide
(BAPNA), Apro from bovine lung, Span 80, magnesium
stearate (Sigma Chemicals, St. Louis, MO); silicon anti-
foaming, cyclohexane, ethyl ether (Merck KGaA,
Germany); acetone, liquid paraf®n and ethyl alcohol (JoseÂ
Vaz Pereira, Portugal).
2.2. Preparation of core materials
Core material was constituted by a bulking agent, casein
from bovine milk, with or without the model drug Apro
incorporated. Bulking agent and Apro powders, at 100:1±
300:1 weight ratios, were simply mixed thoroughly. The
particle sizes of the powders were within the range of
250±500 mm.
2.3. Preparation of microcapsules
CAP microparticles were prepared by a simple emulsion,
solvent evaporation method, based on the ones reported by
Silva and Ferreira [7]. The polymer was dissolved in 10:1
mixtures (20 ml) of acetone/98% ethanol, at a 5±10% (w/v)
concentration. Variable amounts of core material, in the
powder form, were dispersed in this solution by magnetic
stirring. Liquid paraf®n (120 ml) containing 1% (w/v) Span
80 was then placed in a 400 ml beaker, and agitated at 450
revs./min with a three-bladed propeller stirrer (diameter, 5
cm) linked to a stirring motor (Tecmatic SD2). The above
dispersion was then poured into the paraf®n. The solvent
was evaporated at room temperature for 5±7 h. The micro-
capsules were collected in a Buchener ®lter, washed 2±3
times with ethyl ether, and dried at room temperature for
24 h.
E RSPO (2.5 g), followed by 0.15 g magnesium stearate,
was dissolved in 30 ml acetone, and then 0.5±1.5 g of
protein powder was dispersed in the solution. The suspen-
sion was added to 150 ml paraf®n containing 0.5 ml Span
80, as above. Solvent evaporation took, on average, 4 h.
Microcapsules were recovered by ®ltration, washed with
cyclohexane, and dried as before. This corresponds to a
modi®cation of the techniques reported by Goto et al. [8].
The procedure for preparing the E S100 particles was
based on the one employed by Lorenzo-Lamosa et al. [9].
The polymer (2 g) was dissolved in 30 ml of acetone/ethanol
(2:1, v/v). Casein or core powder mixture (1±4 g) was
dispersed in the polymer solution, and the suspension was
then dispersed in 100 ml liquid paraf®n containing 1% (v/v)
Span 80 and 0.1% (v/v) silicon antifoaming. The remaining
steps were as in the previous protocol, but total evaporation
of the solvent took, in this case, 15±17 h.
2.4. Particle sizing and morphological characterization of
the particles
Particle size distributions were carried out by sieving
analysis, using a series of laboratorial sieves with apertures
between 125±1800 mm.
Examination of the surface morphology and cross-
sections of the microparticles were performed by scanning
electron microscopy (SEM; Jeol, JSM ± 5600 LV Scanning
Electron Microscope). The microparticles had no special
treatment for SEM analysis and were cross-sectioned by
pressure with a sharp scalpel.
2.5. Release studies
Release studies of the proteins from the microcapsules
were performed under sink conditions, in sealed plastic
tubes immersed in a water bath (JULABO, SW-20C, Portu-
gal), with the temperature maintained at 378C, and agitated
at 100 revs./min. For the ®rst 2 h, microcapsules (,100 mg)
were suspended in 20 ml of 0.1 M HCl, then this solution
was decanted and replaced with 0.1 M HCl/2 M Na3PO4 (pH
6.8). Samples (1 ml) were removed at appropriate time
intervals, and passed through 45 mm ®lters.
2.6. Determination of total protein and Apro contents
Total protein determinations were carried out by the
Lowry method, using a calibration curve obtained with a
standard solution of casein. Apro in solution was quanti®ed
by a trypsin inhibition assay, that uses BAPNA as a
substrate [10], and using calibration curves obtained with
the same chemicals and reaction conditions. The validity of
the method for the different conditions employed was
always veri®ed.
3. Results and discussion
3.1. Particle morphology
Fig. 1A illustrates size distributions for particles coated
with CAP, at two different polymer/core ratios (1:3 and
1:1.7, g/g). In both cases, more than 90% (weight %) were
in the range of 0.5±2 mm, with mean particle diameters of
1±1.2 mm. Regarding the acrylate particles, Fig. 1B shows
that the E S100 microcapsules were in the same size range
as the CAP ones, but the E RSPO particles had a smaller
mean particle diameter. Although only one batch is illu-
strated in Fig. 1B for E RSPO, three other batches were
sized with a different set of sieves, with identical conclu-
sions. Nevertheless, it should be mentioned that, despite
careful control of experimental variables, such as the stir-
ring rate and temperature of solutions, particles of repetitive
batches sometimes did not exhibit very reproducible size
distributions.
The particles were regularly shaped (Fig. 2), with a more
or less pronounced porous structure. SEM suggested that the
E RSPO capsules were the least porous. Regarding the
dispersion of the core material, their morphologies corre-
spond to either the reservoir type, with single or multiple
powder cores, or to the monolithic structure. A more de®nite
conclusion is dif®cult to reach with this procedure, as
powder leakage may occur when preparing the particles
for the cross-sectional views.
3.2. Microencapsulation yields
The overall yields of the procedures were evaluated by
comparing the initial weight of polymer plus core material
with that of the recovered, dried microparticles. The protein
yields take into account only the protein content of the
particles, as determined by complete dissolution studies.
Table 1 lists the values of these parameters for the CAP-
coated particles, at different initial weights of CAP and
casein. Protein yields were above 50%, and overall process
yields were above 80%, in all but one case. At low CAP/
casein ratios, these parameters were both above 90%.
Table 2 lists the same parameters for the E RSPO and E
S100 particles. For the former, and at the high polymer/core
ratio of 2.5:0.5, an average of 76% of the protein was encap-
sulated, but the overall yield was only 17%. This value is
explained by the presence of polymer in excess, that was
observed to deposit on the propeller and, to a lower extent,
on the vessel wall during the preparation. At a 2:1 ratio, the
yields were signi®cantly higher. With E S100, on the other
hand, the protein was totally recovered in the particles, and
excess of polymer occurred at ratios above 2:1 (g/g; data not
shown).
3.3. Release studies
In order to simulate conditions through the GI tract, the
microparticles were incubated for 2 h in acidic medium,
followed by incubation in a phosphate buffer at neutral
pH. Due to the high dilution of Apro in the powder mixtures
with casein, the release of total protein (essentially casein)
and that of Apro were measured separately, by distinct
procedures. For Apro, an enzymatic method was used,
which is more relevant than just peptide content, as any
biological deactivation during particle preparation would
be evaluated as well.
Fig. 3 shows the release pro®les for casein (total protein)
from particles coated with CAP, at different weight ratios of
the two materials. In all experiments, no release of protein
was observed in HCl medium. After transferring to pH 6.8
buffer, the casein content in solution increased progres-
sively, for approximately 3 h. There were no signi®cant
differences in the release rates or in the time for total release
among particles prepared with different amounts of CAP
and casein (Fig. 3).
The release of Apro was followed for the particles with a
CAP/casein ratio of 1:3, which were selected due to their
higher yields. Fig. 4 shows that, in acidic medium, the Apro
was retained in the particles to a great extent. After placing
them in phosphate solution, over 90% of the Apro content
was released in just half an hour. For comparison, Fig. 4
includes the release of casein.
The total protein release from the particles prepared with
the two Eudragit types can be seen in Fig. 5. The release
pro®les of casein from different E RSPO particles were
similar, and slightly faster than the release from the E
S100 ones. Analogous observation holds for the release of
Apro (Fig. 6). However, while casein was completely
retained in the particles in acidic medium, for Apro, some
leaching was observed. During the 2 h incubation period,
the E RSPO particles lost approximately half of the Apro,
but the E S100 ones released only 20%, a value similar to
the CAP particles. The results with E RSPO are not surpris-
ing, since this polymer is not designed for enteric forms.
Once in solution, it becomes slightly permeable and swells,
therefore with increased pore size. Also, the smaller size of
these particles (Fig. 1) may result in shorter release times.
The faster release of Apro, compared with that of casein,
in phosphate buffer, is due to one or both of the following
Fig. 1. (A) Size distributions for microcapsules of casein coated with CAP,
as determined by sieving analysis. Values are averages ^ SD of three
batches, in each case. (B) Size distributions for microcapsules of casein
coated with E RSPO or E S100, as determined by sieving analysis. The
values for E S100 particles are averages ^ SD of three batches, and those
for E RSPO particles are of a single representative batch.
factors. When the capsules are changed to this medium, the
Apro is already hydrated, while the casein powder has to
initiate its dissolution. The smaller size of Apro (MW, 6
kDa) enables it to diffuse out from the polymer structure
(Fig. 2) faster or earlier than casein. The in¯uence of the
MW in the release pattern was also observed in microcap-
Table 1
Yield determinations of casein microcapsules coated with CAPa






2:1.0 (n 3) 79 55
2:2.0 (n 2) 72 70
1:1.0 (n 2) 86 52
1:1.7 (n 3) 94 90
1:3.0 (n 3) 97 96
a Values are averages of n batches, differing by no more than 10%.
Fig. 2. Scanning electron micrographs for microparticles of CAP, E RSPO and E S100. The voltage applied was 20 kV. Bars correspond to 100 mm: (A), 75 £
resolution; and (B), 100 £ resolution of microcapsules CAP/casein, 1:3. (C) 100 £ ; and (D), 100 £ resolution of microcapsules E RSPO/casein, 2.5:0.5. (E)
90 £ ; and (F), 85 £ resolution of microcapsules E S100/casein, 1:2. (A), (C) and (D) are entire particles, while (B), (D) and (F) are cross-sectional views.
Table 2










RSPO (n 4) 2.5:0.5 17 76
RSPO (n 2) 2:1 53 94
S100 (n 3) 2:4 98.5 98.5
a Values are averages of n batches, differing by no more than 10%.
sules containing casein hydrolysate as the major core mate-
rial, instead of casein. That hydrolysate contains mainly
single amino acids, with a few percent of short oligopep-
tides. In this case, the hydrolysate was totally and quickly
released in HCl medium, while the Apro was retained to a
great extent (data not shown). These results, as regards CAP
microcapsules in acidic solution, are also in agreement with
previous ones for non-protein drugs [7], that showed that
low MW molecules leach from the particles, while larger
ones are retained by the polymeric structure.
We note that samples of hydrochloric acid solutions were
evaluated for Apro bioactivity soon after being collected,
but that Apro is particularly resistant to inactivation by low
pH environments. No loss of activity was observed after a
48 h incubation in 0.1 M HCl solution. However, with other
proteins, different protocols for evaluating release and
bioactivity in simulated gastric media might need to be
adopted.
4. Conclusions
In this work, it was found that the single emulsion/solvent
evaporation methods employed were adequate for microen-
Fig. 4. Comparison between release of total protein (as measured by the
Lowry method), and release of Apro (as measured by the enzymatic assay)
for microcapsules CAP/protein at 1:3 ratio. Results are averages ^ SD of
three independent batches.
Fig. 5. Release of protein for microcapsules of E RSPO and E S100. The
values for E RSPO/casein 2.5:0.5 and for E S100/casein 2:4 are averages ^
SD of three batches, and those for E RSPO/casein 2:1 are averages of two
batches.
Fig. 3. Release of protein for CAP/casein microcapsules, as measured by
the Lowry method. Results are averages ^ SD of three independent
batches, in each case.
Fig. 6. Release of Apro for microcapsules coated with E RSPO and E S100.
The values for E RSPO/protein 2:1 and E S100/protein 2:4 are averages of
two batches, while those for E RSPO/protein 2.5:0.5 are averages of three
batches.
capsulating casein and Apro in the powder forms. Also, the
biological activity of Apro was not affected.
Both CAP and E S100 microcapsules represent interest-
ing forms for delivering small MW proteins, such as Apro,
to the intestine, avoiding exposure to gastric conditions.
However, with CAP particles, release of the active agents
can take place in a proximal part of the intestine, while the
release can be delayed to lower parts of the intestine with E
S100 ones. In vivo studies will elucidate the potential of
these forms in dealing with the extremely common, diverse,
and therapeutically challenging conditions of in¯ammation
of the intestines.
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